Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Kroger Co.
KRConsumer StaplesGenerated Aug 19, 2026, 11:14 PM UTC
KR (Kroger Co.) analytical snapshot. Revenue grew +0.4% YoY to $147.64B. 5-year revenue CAGR +1.4%; 10y CAGR +2.8%. Net margin at 0.69% (contracting ▼). Market cap $34.47B at $56.27 per share. Trailing P/E 36.54, P/S 0.23, P/B 5.33. EV/Operating income ≈ 24.86 (EV $46.98B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -12 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Mar 31, 2026. Latest quarterly report (10-Q) filed Jun 26, 2026. 9 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Mar 31, 2026.
- Latest quarterly report (10-Q) filed Jun 26, 2026.
- 9 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Kroger Co.; broad institutional reporting.
- Recent filers include BERKSHIRE HATHAWAY INC (BRK-A, BRK-B), TradeLink Capital LLC, BERKSHIRE HATHAWAY INC (BRK-A, BRK-B).
- 4 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 16 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | May 15, 2026 |
| TradeLink Capital LLC | 13F-HR | Aug 3, 2015 |
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | Aug 14, 2026 |
| SILVER CAPITAL MANAGEMENT LLC | 13F-HR | Nov 17, 2009 |
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | Feb 17, 2026 |
| Date | Form | Description |
|---|---|---|
| Jul 1, 2026 | 8-K | FORM 8-K |
| Jun 26, 2026 | 8-K | FORM 8-K |
| Jun 18, 2026 | 8-K | FORM 8-K |
| May 27, 2026 | 8-K | FORM 8-K |
| Mar 5, 2026 | 8-K | FORM 8-K |
| Feb 9, 2026 | 8-K | FORM 8-K |
| Dec 4, 2025 | 8-K | FORM 8-K |
| Nov 18, 2025 | 8-K | FORM 8-K |
SEC Filing Deep-Analysis
4 risk signal(s), 1 positive signal(s) detected from XBRL filing diff analysis. 4 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" "substantial doubt" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
- Material weakness in internal controls: The term "material weakness" "internal control" appears in 3 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 3 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
- Operating cash flow exceeds net income: OCF is 7.20x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: 4 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Going concern doubt, Substantial doubt about ability to continue.
- Ongoing high-severity risk language: Material weakness in internal controls, Restatement of financial statements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $147.12B | $147.64B | $519.0M | +0.4% |
| Operating income | $3.85B | $1.89B | $-1.96B | -50.9% |
| Net income | $2.67B | $1.02B | $-1.65B | -61.9% |
| Operating cash flow | $5.79B | $7.31B | $1.52B | +26.2% |
| Capex | $4.02B | $3.85B | $-162.0M | -4.0% |
| Total assets | $52.62B | $49.95B | $-2.66B | -5.1% |
| Total liabilities | $44.34B | $44.02B | $-318.0M | -0.7% |
| Long-term debt | $15.91B | $15.88B | $-34.0M | -0.2% |
| Cash & equivalents | $3.96B | $3.33B | $-625.0M | -15.8% |
| Stockholders equity | $8.29B | $5.93B | $-2.36B | -28.5% |
| Interest expense | $535.0M | $441.0M | $-94.0M | -17.6% |
| Type | Concepts |
|---|---|
| Removed | AdvertisingExpense, AllocatedShareBasedCompensationExpense, AmortizationOfIntangibleAssets, AssetsHeldForSaleLongLivedFairValueDisclosure, AssetsHeldForSaleNotPartOfDisposalGroup, BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1, ContractWithCustomerLiability, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 2 | 0 | NEW |
| Material weakness in internal controls | high | 3 | 2 | Ongoing |
| Substantial doubt about ability to continue | high | 2 | 0 | NEW |
| Restatement of financial statements | high | 3 | 1 | Ongoing |
| Impairment charge | medium | 5 | 2 | Ongoing |
| Restructuring | medium | 5 | 4 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 2 | Ongoing |
| Related party transactions | low | 5 | 0 | NEW |
Fundamentals
Revenue grew +0.4% YoY to $147.64B. 5-year revenue CAGR +1.4%; 10y CAGR +2.8%. Net margin at 0.69% (contracting ▼).
- Revenue grew +0.4% YoY to $147.64B.
- 5-year revenue CAGR +1.4%; 10y CAGR +2.8%.
- Net margin at 0.69% (contracting ▼).
- Return on equity 17.14%, ROA 2.03%, ROIC 8.67%.
- Gross margin 0.00%, operating margin 1.28%.
- Free cash flow margin 2.34% ($3.46B).
- Net income down ▼ +61.9% YoY.
- Debt/equity 2.38, current ratio 0.79, net debt $12.51B.
- Asset turnover 2.94 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2025 | $147.12B | -1.9% | 0.00 | 2.62 | 1.81 | $1.78B | 32.17 |
| 2026 | $147.64B | +0.4% | 0.00 | 1.28 | 0.69 | $3.46B | 17.14 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Aug 17, 2024 | $33.91B | — | — | 1.37% |
| Nov 9, 2024 | $33.63B | — | -0.8% | 1.84% |
| May 24, 2025 | $45.12B | — | +34.1% | 1.92% |
| Aug 16, 2025 | $33.94B | — | -24.8% | 1.79% |
| Nov 8, 2025 | $33.86B | — | -0.2% | -3.90% |
| May 23, 2026 | $46.12B | — | +36.2% | 1.96% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $34.47B at $56.27 per share. Trailing P/E 36.54, P/S 0.23, P/B 5.33. EV/Operating income ≈ 24.86 (EV $46.98B).
- Market cap $34.47B at $56.27 per share.
Price & Technicals
Price $56.27 — downtrend (below 200-DMA); 1-month momentum negative. RSI(14) 38.15.
- Price $56.27 — downtrend (below 200-DMA); 1-month momentum negative.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 2.38 (high). Liquidity current ratio 0.79 (stretched).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -12
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Kroger Co. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewMarket cap $34.47B at $56.27 per share..
Peer comparison
Defensive groupHow KR stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 19 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Walmart Inc. WMT | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR● you | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |